InvestorsHub Logo
Followers 826
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Monday, 12/06/2021 11:20:18 AM

Monday, December 06, 2021 11:20:18 AM

Post# of 749
Rinvoq hits_primary/secondary_endpoints_in phase-3 trial_in_second-line Crohn’s disease:

https://finance.yahoo.com/news/upadacitinib-rinvoq-achieved-primary-key-133000723.html

Detailed results will be presented at an unspecified medical conference. A second phase-3 Rinvoq trial in Crohn’s has yet to read out.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News